

ethnicity disparities exist in the association between diabetes and pancreatic cancer. **METHODS:** In a retrospective cross-sectional study, community-dwelling and institutionalized Medicare beneficiaries aged 65 or over without health maintenance organization enrollment from the Medicare Current Beneficiary Survey (MCBS) from 2001 to 2010 were included. The outcome of the study was pancreatic cancer; and the key explanatory variables were diabetes and race/ethnicity. Potential confounders considered included age, gender, education, marital status, income, residence area, body mass index (BMI), smoking status, Charlson comorbidity index (CCI), and use of preventive services. The International Classification of Diseases-9 codes were used to identify the outcome and explanatory variables from the Medicare Part A and B claims. Logistic regressions were performed to estimate the association between diabetes and pancreatic cancer. **RESULTS:** A total of 98,966 person-years of elderly Medicare beneficiaries were included in the analysis. After controlling for potential confounders, the association between diabetes and pancreatic cancer was statistically significant (odds ratio [OR], 3.15; 95% confidence interval [CI], 2.07–4.77). Compared to non-Hispanic whites, non-Hispanic blacks (OR, 0.43; 95% CI, 0.15–1.20) and Hispanics (OR, 0.78; 95% CI, 0.33–1.85) had similar risks of pancreatic cancer. **CONCLUSIONS:** This study found that diabetes is associated with pancreatic cancer in the elderly Medicare population. However, racial/ethnicity differences do not explain the association between diabetes and pancreatic cancer.

#### PCN7 COMORBIDITY AND POSTOPERATIVE OUTCOMES AMONG LUNG CANCER PATIENTS IN THE UNITED STATES

Nadpara PA

Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA

**OBJECTIVES:** The burden of comorbid illness is known to be higher among lung cancer patients and it's also shown to impact survival outcomes. However, the influence of comorbidity on in-hospital surgical outcomes among lung cancer patients remains unknown. Therefore, this study examined the effect of comorbidity on risk of post-operative complications, prolonged hospitalization, and in-patient death among lung cancer patients following surgery. **METHODS:** A retrospective analysis of hospital discharge data from the 2011 Health Care Utilization Project - Nationwide Inpatient Sample (HCUP-NIS) database was performed. Discharges of patients who underwent surgery for lung cancer during 2011 were identified. Information about patients and hospitals characteristics were obtained. Comorbidities were identified and used to calculate Charlson comorbidity index score. Patients were then divided based on these scores into four groups: 0, 1, 2, and  $\geq 3$ . Multivariate logistic regression analyses was used to examine risk adjusted association between comorbidity score and the study outcomes. **RESULTS:** We identified 19,564 patients' discharges that meet our inclusion criteria. Compared to patients with no comorbid conditions, patients with one or more comorbid conditions saw a two-fold increase in the risk of post-operative complications ( $p < 0.001$ ). The risk of prolonged hospitalization was also higher among patients with a comorbidity score of 1, 2, or  $\geq 3$ , compared to patients with a comorbidity score of zero ( $p < 0.001$ ). Higher comorbidity burden also increased the risk of in-patient death by three folds ( $p < 0.001$ ). **CONCLUSIONS:** In-hospital outcomes among lung cancer patients following surgery are negatively impacted by presence of comorbid illness. Post-operative morbidity and mortality among these patients may be reduced if their comorbid conditions are managed effectively.

#### PCN8 INCREASED PREVALENCE OF LIPID DISORDERS IN CANCER PATIENTS ADMITTED TO U.S. HOSPITALS

Delgado A<sup>1</sup>, Villarreal SM<sup>1</sup>, Koeller JM<sup>1</sup>, Frei BL<sup>2</sup>, Frei CR<sup>1</sup>

<sup>1</sup>The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA, <sup>2</sup>University of the Incarnate Word, San Antonio, TX, USA

**OBJECTIVES:** Some new cancer therapies are associated with prolonged patient survival; therefore, management of chronic comorbidities in cancer patients has become more important. We sought to measure the prevalence of lipid disorders, and other chronic comorbidities, among cancer patients admitted to U.S. hospitals over a 14-year period. **METHODS:** We utilized data from the U.S. National Hospital Discharge Surveys from 1996 to 2009. We limited the study to patients  $\geq 18$  years of age with a primary discharge diagnosis of lung, breast, prostate, or colorectal cancer (ICD-9-CM codes 162, 174, 185, and 153, respectively). Data weights were used to derive national estimates. The prevalence of diabetes (250), ischemic heart disease (410-414), heart failure (428), cerebrovascular disease (430-438), and lipid disorders (272) was calculated for each year and cancer type. **RESULTS:** Roughly 6 million visits were represented over the 14-year study period (lung 2.1, breast 1.3, prostate 1.3, and colorectal cancer 1.6 million). One-third of patients admitted with cancer had at least one comorbidity, and 8% had at least two comorbidities over the entire 14-year study interval; however, the rates of comorbidity changed drastically over time—particularly for lipid disorders. Of the patients admitted with lung cancer in 1996, only 2% had lipid disorders, compared to 13% in 2009. Similar patterns were observed for those patients admitted with breast cancer (2% to 17%), prostate cancer (3% to 30%), and colorectal cancer (2% to 12%). Prevalence of diabetes and ischemic heart disease also increased, but to a lesser extent. **CONCLUSIONS:** Management of lipid disorders in patients with cancer has become increasingly important. U.S. studies focused on improving cancer mortality, as well as the rising costs of care, should increasingly take chronic conditions—particularly lipid disorders—into account.

#### PCN9 PRE-EXISTING TYPE 2 DIABETES MELLITUS AND EMERGENCY COLORECTAL SURGERY AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER

Deb A, Madhavan SS, Bose S, Sambamoorthi U

West Virginia University, Morgantown, WV, USA

**OBJECTIVES:** To examine the association between pre-existing Type 2 Diabetes Mellitus (T2DM) and risk of emergency colorectal surgery among elderly patients with colo-

rectal cancer (CRC) after controlling for other risk factors. **METHODS:** We identified a cohort of 37,044 elderly Medicare beneficiaries with incident CRC between 2003 and 2009 who had colorectal surgery using the SEER-linked Medicare database. T2DM was identified using the ICD-9-CM (International Classification of Diseases, 9th Revision, and Clinical Modification) codes during the 12-months prior to incident diagnosis of CRC. CRC surgery was identified with procedure codes for colon resection, rectal resection, and other operations on the intestine including colostomy and ileostomy. If individuals with CRC had ICD-9-CM codes indicative of bowel perforation, peritonitis, or obstruction, they were considered to have emergency surgery. Chi-square tests and logistic regression were used to analyze the association between pre-existing T2DM and emergency surgery after adjustments for sex, race/ethnicity, age, cancer site, stage, region, and office visits in the 12 months prior to incident cancer. **RESULTS:** Unadjusted rates of emergency surgery were significantly lower among CRC patients with pre-existing T2DM compared to CRC patients without diabetes (9.8% vs. 11.4%). This association, however, was not significant in adjusted analyses. CRC patients with highest number of annual office visits were significantly less likely than CRC patients with lowest number of annual office visits to receive emergency surgery (AOR=0.69; 95%CI=0.61, 0.78). Other risk factors for emergency surgery in CRC patients were old age (80-84 years: AOR=1.15, 95%CI=1.03, 1.29; 85 years and above: AOR=1.41, 95%CI=1.26, 1.58), and late stage at diagnosis (regional stage: AOR=2.14, 95%CI=1.99, 2.31; distant stage: AOR=2.78, 95%CI=2.54, 3.05). CRC patients with atherosclerosis were less likely to have emergency surgery compared to those without atherosclerosis (AOR=0.89; 95%CI=0.82, 0.97). **CONCLUSIONS:** Pre-existing T2DM was not associated with emergency surgery after controlling for a comprehensive list of risk factors.

#### PCN10 PATTERNS OF CARE IN THE WORKUP AND MANAGEMENT OF NON-METASTATIC AND METASTATIC COLORECTAL CANCER

Seal LB<sup>1</sup>, Shermock KM<sup>2</sup>, Asche CV<sup>3</sup>, Kreilick C<sup>1</sup>, Tangirala M<sup>1</sup>, Cameron J<sup>1</sup>, Kish J<sup>4</sup>, Zagadailov EA<sup>4</sup>, Eaddy M<sup>4</sup>

<sup>1</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>The Johns Hopkins Medical Institutions, Baltimore, MD, USA, <sup>3</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>4</sup>Xcenda, Palm Harbor, FL, USA

**OBJECTIVES:** NCCN guidelines recommend that non-metastatic colorectal cancer (CRC) patients receive a comprehensive work-up including detailed imaging studies. The purpose of this study was to evaluate physician concordance to NCCN guidelines in terms of the receipt of tests and procedures during the 6-month period prior to a patient's CRC diagnosis. **METHODS:** A large integrated claims database spanning January 2008 to September 2013 was used to identify patients  $\geq 50$  years old diagnosed and treated for CRC. Patients were required to be continuously enrolled for  $\geq 6$  months pre- (baseline period) and  $\geq 3$  months post-diagnosis. Eligible patients were stratified into cohorts based on the occurrence and timing of metastatic (M) disease: no metastases (NM),  $\leq 90$  days (M1), and  $\geq 90$  days (M2) from initial diagnosis. Tests evaluated included disease-appropriate CT or MRI, ultrasound, blood and fecal screenings, baseline biopsy, CEA, endoscopy, PET-CT, proctoscopy, sigmoidoscopy, and colonoscopy. **RESULTS:** There were 15,182 patients meeting study criteria, with 77.8% being NM, 11.2% M1, and 11.0% M2. Over 75% of patients had a health physical in the baseline period but only 43.3% received fecal or blood-based screenings. The most common invasive procedure was colonoscopy, occurring in 9.6% of M1, 13.7% of M2, and 11.7% of NM patients. Less than 20% of NM patients (17.8%) received a chest, abdominal, or pelvic CT or MRI compared to 20.7% of M1 and 33.8% of M2 patients. Twice as many M2 patients (30.9%) received a CEA test compared to 15.1% of M1 and 24.6% of NM patients. Biopsy, ultrasound (including endorectal), proctoscopy, and sigmoidoscopy were documented in less than 5% of all patients. **CONCLUSIONS:** In this population of CRC patients, concordance to NCCN guidelines was low, with NM patients receiving a lesser degree of complete work-up per guidelines compared with M patients.

#### PCN11 THE BURDEN OF AML WITHIN THE

Turbeville S<sup>1</sup>, Francis KM<sup>2</sup>, Behm I<sup>2</sup>, Chiu GR<sup>2</sup>, Sanchez H<sup>2</sup>, Morgan J<sup>1</sup>, Yakovich A<sup>1</sup>, Ward R<sup>1</sup>, Hyare P<sup>1</sup>

<sup>1</sup>Sunesis Pharmaceuticals, South San Francisco, MA, USA, <sup>2</sup>Trinity Partners, Waltham, MA, USA

**OBJECTIVES:** While cancer registries such as SEER currently serve as the largest source of cancer epidemiology, recent research (Cogle, et al., 2012) has suggested that these registries may be underreporting AML due to methodological limitations. Using a claims-based algorithm, we estimated the incidence of acute myeloid leukemia (AML) in the <65 year-old US population. **METHODS:** A retrospective analysis of claims was performed using 2010-2012 IMS Health LifeLink PharMetrics Plus (LifeLink), a longitudinal medical claims dataset comprised of adjudicated claims of >150 million unique enrollees. LifeLink is representative of the US commercially-insured population aged  $\leq 65$ . AML diagnoses were identified using ICD-9 codes and AML treatments were identified using CPT/HCPCS codes and ICD-9-CM infusion codes. Patients with  $\geq 2$  claims including AML diagnoses codes OR one AML medical claim and one AML treatment in 2012 were defined as prevalent AML patients. A sub-population of all prevalent AML patients without historical AML diagnoses or treatments during the prior two years were identified as new (incident) AML patients. Results were stratified by gender and age (<18, 18-39, 40-49, 50-59, 60-64 years). **RESULTS:** The overall 2012 incidence of the <65 population was 5.4 per 100,000 (95% CI: 5.2, 5.6), with incidence incrementally increasing with age (i.e., lowest in the <18 cohort [3.2 per 100,000] and highest in the 60-64 cohort [12.3 per 100,000]). Incidence among males was slightly higher than among females, 5.7 (95% CI: 5.3, 6.0) and 5.2 (95% CI: 4.9, 5.5) per 100,000, respectively. Males 60-64 had the highest incidence rate, 13.5 per 100,000 (95% CI: 11.7, 15.2). **CONCLUSIONS:** Our 2012 AML incidence estimates are substantially higher than published SEER estimates for the <65 population: 5.4 per 100,000 vs. SEER's 1.8 per 100,000, respectively. Thus, the current AML burden of disease may be underestimated, further justifying the need for earlier detection and more efficacious treatment options.